Literature DB >> 3995701

Effects of propranolol on atherogenesis in the cholesterol-fed rabbit.

A V Chobanian, P Brecher, C Chan.   

Abstract

These studies have examined the effects of dl-propranolol, d-propranolol, and metoprolol on aortic atherogenesis in the cholesterol-fed rabbit and have correlated the vascular effects of the drugs with their influence on blood pressure, plasma lipids and lipoproteins, arterial metabolism, and arterial permeability. dl-Propranolol, and, to a lesser extent, d-propranolol, used in clinically relevant doses of 5 mg/kg body weight per day, inhibited the development of aortic atherosclerosis in association with significant reductions in aortic free and esterified cholesterol content. No significant effects of the drugs on blood pressure or on the total amounts or types of circulating lipoproteins were apparent. Accumulation of cholesterol in the liver and adrenal gland was not influenced by propranolol. Aortic acyl CoA:cholesterol acyltransferase and lysosomal enzyme activities were reduced by propranolol administration, but the inhibition may have been secondary to the lesser degrees of atherosclerosis and cholesterol accumulation present. In vitro inhibition of acyl CoA:cholesterol acyltransferase activity by either dl- or d-propranolol was also observed, but occurred only at propranolol concentrations of 10(-3) M or greater. Treatment with dl-propranolol had no significant effect on the rate of transport of labeled albumin across the isolated carotid artery of cholesterol-fed rabbits. Metoprolol administration (6.25 mg/kg body weight per day) had no significant influence on atherogenesis or arterial metabolism in this model. The results suggest that propranolol inhibits in part the development of atherosclerosis in the cholesterol-fed rabbit, and that the effect may be related to a direct action on the arterial wall.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3995701     DOI: 10.1161/01.res.56.5.755

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

Review 1.  Combined action drugs in the treatment of hypertension.

Authors:  L Hansson
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment.

Authors:  J W Knowles; R L Reddick; J C Jennette; E G Shesely; O Smithies; N Maeda
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

3.  Beta blockers, lipids, and coronary atherosclerosis: fact or fiction?

Authors:  R J Northcote
Journal:  Br Med J (Clin Res Ed)       Date:  1988-03-12

Review 4.  The potential for added benefits with beta-blockers and calcium antagonists in treating cardiovascular disorders.

Authors:  W G Nayler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 5.  Interrelationship of hypertension, plasma lipids and atherosclerosis.

Authors:  J M Krzesinski; P G Carlier; G L Rorive
Journal:  Drugs       Date:  1988       Impact factor: 9.546

Review 6.  Heart rate as a risk factor for atherosclerosis and cardiovascular mortality: the effect of antihypertensive drugs.

Authors:  P Palatini
Journal:  Drugs       Date:  1999-05       Impact factor: 9.546

Review 7.  Modification of atherosclerosis by agents that do not lower cholesterol.

Authors:  J G Cleland; D M Krikler
Journal:  Br Heart J       Date:  1993-01

8.  Verapamil and diet halt progression of atherosclerosis in cholesterol fed rabbits.

Authors:  R E Sievers; T Rashid; J Garrett; S Blumlein; W W Parmley
Journal:  Cardiovasc Drugs Ther       Date:  1987       Impact factor: 3.727

9.  Noninvasive assessment of lipid disposition in treated and untreated atherosclerotic rabbits.

Authors:  L E DeForge; S W Schwendner; M R DeGalan; D S McConnell; R E Counsell
Journal:  Pharm Res       Date:  1989-12       Impact factor: 4.200

10.  Chronic ACE inhibition reduces intimal hyperplasia in experimental vein grafts.

Authors:  M K O'Donohoe; L B Schwartz; Z S Radic; E M Mikat; R L McCann; P O Hagen
Journal:  Ann Surg       Date:  1991-12       Impact factor: 12.969

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.